Mellar P. Davis – författare

50 Pharmacotherapy Studies Every Palliative Practitioner Should Know is a compilation of key pharmacotherapy studies that form the foundation of evidence-based practice. The studies cover topics including: agitation and delirium, fatigue, nausea and vomiting, pain, anorexia and cachexia, ALS, seizure, dyspnea, anxiety, pruritis, symptom clusters, COPD, cancer, and more. For each study, a concise summary is presented with an emphasis on the results and limitations of the study, and its implications for practice. Brief information on other relevant studies is provided, and an illustrative clinical case offers readers the opportunity to conceptualize findings. As with all books in the "50 Studies" series, each study was selected using an objective selection criterion that included citations per year, high levels of evidence, clinical studies and trials, and a 3-stage Delphi review by international experts in the field. This book is a must-read for palliative practitioners, pharmacists, advance practice nurses, and physician assistants, and anyone who wants to learn more about the data behind clinical practice.

The first book of its kind, this must-have resource examines the integration of palliative interventions from a disease-specific approach, providing practical guidance on caring for patients who follow a progressive, chronic disease trajectory prior to death. This uniquely practical book addresses all aspects of palliative care, going beyond theoretical information to advise practitioners on the most effective management of common symptoms and providing physical, psychological, and spiritual comfort to patients and families. The multidisciplinary focus of care is reflected by collaborative contributors and diverse authorship of an oncology/palliative care nurse practitioner, a physician, and a social worker.

The use of cannabinoid-based medicines (CBM), and cannabis in particular, has risen steadily among cancer and palliative care patients over the last few years.

The use of cannabinoid-based medicines (CBM), and cannabis in particular, has risen steadily among cancer and palliative care patients over the last few years. This textbook aims to address the multiple challenges facing healthcare providers regarding the use of CBM in this vulnerable patient population. It provides insight into the latest preclinical and clinical data and offers a practical approach on the use of CBM in a rapidly evolving landscape. It answers questions regarding the prescribing process and elucidates controversies regarding cannabis’ disease-modifying effects. The first chapters will review basic concepts of the endocannabinoid system and pharmacology of CBM, while focusing more specifically on the unique characteristics of two main cannabinoids: THC and CBD. Indicating which benefits can be expected from using either or both of these compounds, the book then addresses issues of drug-drug interactions and other challenges involved in prescribing CBM to frail patientswith polypharmacy and multiple comorbidities. Comparing available products, both approved and non-approved by the FDA, the book discusses regional challenges for accessing reliably tested and labelled products in the context of standardization efforts. After carefully determining objectives and addressing patient expectations, further chapters will examine the different clinical settings in which CBM may be useful in cancer care and explore symptom management, including cancer pain, anxiety, nausea, and insomnia among others. The possible benefits of cannabis psychoactivity will also be discussed, including harm reduction strategies for patients who wish to explore these effects.

Cannabis and Cannabinoid-Based Medicines in Cancer Care: A Comprehensive Guide to Medical Management serves as a comprehensive text for oncologists, palliative care specialists, general practitioners, and nurse practitioners working with cancer patients or in palliative care settings.